Core Viewpoint - The mid-term clinical results of the Cardiovalve transcatheter valve replacement system from the TARGET study demonstrate its safety and clinical performance, highlighting its effectiveness in treating severe tricuspid regurgitation [1] Group 1: Clinical Study Overview - The TARGET study is a prospective, single-arm, multi-center clinical trial conducted across 25 clinical centers in Germany, Spain, Italy, Canada, and the UK, involving 125 patients with an average age of 77 years [1] - The average procedure time for the device was 58±29 minutes, with the shortest recorded procedure time being 16 minutes [1] - The overall intraoperative success rate was reported at 88% according to the TVARC standard, with a success rate of 95% for the device implantation group [1] Group 2: Product Recognition and Future Plans - The mid-term clinical data for the Cardiovalve tricuspid valve replacement system was presented at the PCR London Valves 2025 conference, receiving high recognition from international clinical experts [1] - The company aims to actively advance the global clinical registration and development process for innovative products, including the Cardiovalve system, to expedite market approval and benefit more patients while pursuing its internationalization strategy [1]
启明医疗-B(02500.HK)宣布创新经导管瓣膜置换系统Cardiovalve的TARGET研究中期临床结果